Article

The 32nd annual San Antonio Breast Cancer Symposium gets under way

Author(s):

On November 11, 1978, a group of 141 physicians and surgeons from a five state area got together during Breast Cancer Awareness Week to discuss ways to reduce the death rate caused by breast cancer in San Antonio and surrounding counties. Fast forward 31 years. This year's symposium will host an estimated 8,500 participants from more than 90 countries and instead of gathering for a single day, attendees will stay for five. What began as a novel idea has gained unfathomable momentum. The overall objective of SABCS, however, remains the same. Its mission is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for breast cancer patients.For the next few days, the CURE team will be bringing you updates from this very important gathering of international thought leaders. Not only will we deliver the latest and greatest scientific news surrounding breast cancer, but will also be talking to survivors and advocates about their passionate causes. We'll be blogging, tweeting, writing, and filming daily so be sure to follow us here. Follow us on facebook and twitter too!

Related Videos
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Related Content